TRANSPARENCY COUNCIL MEETING NO. 26/2023 JULY 3, 2023
1. vabysmo (farycymabum) Indication: under the drug program "Treatment of patients with retinal diseases (ICD-10: H35.3, H36.0)". Decision-making problem: preparing a position paper on the evaluation of the drug
2. Ryeqo (relugolixum estradiolum norethisterone acetate) - CONDITIONAL Indication: in the indication resulting from the submitted reimbursement application Decision problem: preparation of a position on the evaluation of the drug
3. polivy (polatuzumabum vedotinum) Indication: under the drug program "Treatment of patients with B-cell lymphoma (ICD-10: C82, C83, C85)". Decision-making problem: preparation of a position paper on the evaluation of the drug
4. imbruvica (ibrutinibum) Indication: under drug program B.79. "Treatment of patients with chronic lymphocytic leukemia (ICD10: C91.1)" Decision-making problem: preparing a position paper on the evaluation of the drug
5. lynparza (olaparibum) Indication: under drug program B.50. "Treatment of patients with ovarian cancer, fallopian tube cancer or peritoneal cancer (ICD-10: C56, C57, C48)." Decision-making problem: preparation of a position paper on the evaluation of the drug
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
